Studies on patients with HER-2 positive undergoing chemotherapy have shown that β2 receptor activation can give rise to chemotherapy resistance in patients.12 Moreover, studies on glioma, non-small cell lung cancer, cervical cancer, and ovarian cancer13-16 have also shown that β-blockers boast of improving the long-term survival rate of patients. This evidence concerns the gene ERBB2 and cervical carcinoma.